A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Martin P. Steinbuck(Io Therapeutics (United States)), Lochana M. Seenappa(Io Therapeutics (United States)), Aniela Jakubowski(Io Therapeutics (United States)), Lisa K. McNeil(Io Therapeutics (United States)), Christopher M. Haqq(Io Therapeutics (United States)), Peter C. DeMuth(Io Therapeutics (United States))
Cited by 54Open Access
Abstract
1 isotypes (IgG2c and IgG3) and potently neutralized Spike-2-ACE2 receptor binding, with titers 265-fold higher than natural convalescent patient COVID-19 responses; T cell and antibody responses were maintained despite 10-fold dose reduction in Spike antigen. Both cellular and humoral immune responses were preserved in aged mice. These advantages merit clinical translation to SARS-CoV-2 and other protein subunit vaccines.
Related Papers
No related papers found
Powered by citation graph analysis